Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of ALXN1840 on human hepatic copper uptake quantified with 64CuCl2 PET/CT
2020-005832-31Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of atn-224 (4 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Mean hepatic SUV comparison. Started Feb 2021; status: completed.
02
Drugs
atn-224
Beyond the preview
Go deeper on 2020-005832-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005832-31.